-
Teekay Offshore Partners L.P. (NYSE: TOO) declined
18.6 percent to $2.71. Morgan Stanley downgraded Teekay Offshore from Equal-Weight to Underweight.
-
Eyegate Pharmaceuticals Inc (NASDAQ: EYEG) shares
dropped 16.7 percent to $1.40 after the company disclosed a $10 million offering of common stock and warrants.
-
Rite Aid Corporation (NYSE: RAD) shares fell 14.3
percent to $3.03 amid report of FTC preparing an advice to block deal with Walgreens.
-
Cloudera Inc (NASDAQ: CLDR) shares declined 14
percent to $19.78. Cloudera reported Q1 adjusted loss of $0.27 per share on revenue of $79.6 million.
-
Endo International plc (NASDAQ: ENDP) tumbled
13.7 percent to $11.90 in reaction to the U.S. Food and Drug Administration's request for the company to withdraw from the
market its opioid painkiller called Opana ER.. Stifel Nicolaus downgraded Endo from Buy to Hold. Stifel Nicolaus downgraded
Endo from Buy to Hold.
-
KMG Chemicals, Inc. (NYSE: KMG) shares declined 12.7
percent to $52.53. KMG reported Q3 adjusted earnings of $0.53 per share on sales of $81.6 million.
-
HNI Corp (NYSE: HNI) dropped 11 percent to $40.01
after the company lowered its earnings forecast.
-
Actuant Corporation (NYSE: ATU) declined 8.6 percent
to $24.88. Actuant lowered its Q3 adjusted earnings guidance.
-
Mesoblast limited (ADR) (NASDAQ: MESO) shares
fell 8.2 percent to $8.15.
-
Teekay Corporation (NYSE: TK) shares slipped 8.1
percent to $5.90. Morgan Stanley downgraded Teekay from Equal-Weight to Underweight.
-
Ferrellgas Partners, L.P. (NYSE: FGP) dropped 5.3
percent to $5.04 as the company posted downbeat quarterly results.
-
CGG SA (ADR) (NYSE: CGG) shares declined 5.3 percent
to $5.13 after dropping 1.73 percent on Thursday.
-
Snap Inc (NYSE: SNAP) slipped 4 percent to $18.06.
Citigroup downgraded Snap from Buy to Neutral.
-
Digital Realty Trust, Inc. (NYSE: DLR) shares
declined 3.4 percent to $112.79 after the company announced plans to merge with DuPont Fabros.
-
VeriFone Systems Inc (NYSE: PAY) fell 3.3 percent to
$17.71 after the company posted a loss for the second quarter and lowered its FY17 outlook.
© 2017 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.